Quantcast

Latest Vancomycin Stories

2011-04-14 12:28:44

NIH study evaluated 18 intensive care units WHAT: Expanded use of active surveillance for bacteria and of barrier precautions"”specifically, gloves and gowns"”did not reduce the transmission of two important antibiotic-resistant bacteria in hospital-based settings, according to a prospective, randomized clinical trial conducted in 18 intensive care units in the United States. Incomplete compliance by health care providers with recommended hand hygiene procedures and the use of...

2011-04-14 12:16:21

A new research study of the effect of a commonly used strategy to reduce the spread of antibiotic-resistant bacteria in hospital intensive care units (ICU) shows that the strategy had no significant effect. That's the surprising finding of a multisite study led by Mayo Clinic investigators. The bacteria -- methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus (VRE) -- are resistant to common antibiotics and harder to treat if patients become infected. The...

2011-04-06 06:00:00

SAN DIEGO, April 6, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) and Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the signing of an exclusive two-year co-promotion agreement to market DIFICID(TM) (fidaxomicin), in the United States. DIFICID is a novel antibiotic currently being reviewed for market approval by the FDA for the treatment of Clostridium difficile infection (CDI), which is also known as Clostridium difficile-associated diarrhea (CDAD)....

2011-04-05 15:48:00

SAN DIEGO, April 5, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration's (FDA) Anti-Infective Drugs Advisory Committee (AIDAC) recommended that the FDA approve Optimer's investigational antibiotic DIFICID(TM) (fidaxomicin) for the treatment of patients with Clostridium difficile infection (CDI), a bacterial infection in the lining of the gut that can cause severe diarrhea, colitis and in some cases death. In a...

2011-04-05 07:00:00

SAN DIEGO, April 5, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced today that NASDAQ has halted trading of the Company's common stock this morning. The Anti-Infective Drugs Advisory Committee (AIDAC) of the U.S. Food and Drug Administration (FDA) is scheduled to meet today to review and discuss Optimer's New Drug Application (NDA) for fidaxomicin for the treatment of Clostridium difficile infection. (Logo:...

2011-04-02 13:00:00

SAN DIEGO, April 2, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today the presentation of information from insurance claims and survey databases highlighting the unmet need for targeted therapies to treat subpopulations at high risk of recurrence of Clostridium difficile infection (CDI). The research also presented the substantial mortality and frequent complications associated with CDI. Investigator Erik R. Dubberke, M.D., M.S.P.H., of the Washington...

2011-03-10 15:05:00

SAN DIEGO, March 10, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced 2010 fourth quarter and full year financial results and accomplishments. (Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO) Optimer reported a net loss for the three months ended December 31, 2010 of $11.9 million, or $0.31 per common share, as compared to a net loss of $9.4 million, or $0.28 per common share, for the same period in 2009. Optimer reported a net loss for...

2011-03-09 06:30:00

EXTON, Pa., March 9, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the company's Board of Directors has authorized the use of up to $150 million to repurchase shares of its common stock and/or its 2% Senior Convertible Notes due 2017. Purchases may be made by means of open market transactions, block transactions, privately negotiated purchase transactions or other techniques from time to time, as determined by ViroPharma's management, and in accordance...

2011-02-28 10:00:00

EXTON, Pa., Feb. 28, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the Citi 2011 Global Healthcare Conference at 2:00 P.M. ET on Wednesday, March 2, 2011. The conference is being held at the Hilton New York Hotel in New York City. Charles Rowland, vice president and chief financial officer, of ViroPharma, will present at the Cowen & Company 31st Annual Healthcare...

2011-02-11 13:22:32

RNA recycling system gone awry brings MRSA to a halt Scientists have discovered a new way to attack dangerous pathogens, marking a hopeful next step in the ever-escalating battle between man and microbe. In a paper published online Feb. 10 in the journal PLoS Pathogens, scientists demonstrate that by stopping bacteria's ability to degrade RNA "“ a "housekeeping" process crucial to their ability to thrive "“ scientists were able to stop methicillin-resistant Staphylococcus aureus...


Latest Vancomycin Reference Libraries

0_4d46cc72a490344d44ba78359f528175
2011-04-26 21:07:20

Enterococcus is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is a main constituent of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans, especially in the nosocomial environment, where the naturally high levels of antibiotic resistance found in E. faecalis contribute to its pathogenicity. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of...

0_71ad70ea6f0948a7e84406e760c7f5a4
2011-04-15 14:36:05

Enterococcus faecalis "“ formerly classified as part of the Group D Streptococcus system "“ is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is one of the main constituents of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of the cases. It is a non-motile, facultatively anaerobic...

More Articles (2 articles) »
Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related